Drugs / Mirodenafil
Mirodenafil
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT02485041 | Nov → Dec 2014 | — | SK Chemicals Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02485028 | Oct → Nov 2013 | — | SK Chemicals Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01232010 | Nov 2009 → Dec 2011 | impaired renal function disease | Asan Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00626743 | May 2008 → May 2009 | hypertensive disorder | SK Chemicals Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT00489606 | Apr → Jun 2007 | erectile dysfunction | SK Chemicals Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT00489450 | Mar → May 2007 | erectile dysfunction | SK Chemicals Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT00443625 | Dec 2006 → Feb 2007 | erectile dysfunction | SK Chemicals Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00351065 | Sep 2004 → Mar 2005 | erectile dysfunction | SK Chemicals Co., Ltd. | Terminated | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT00644007 | Dec 2007 → Sep 2008 | erectile dysfunction | SK Chemicals Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT00705861 | Nov 2007 → Jul 2008 | erectile dysfunction | SK Chemicals Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mirodenafil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02485041 ↗ |
| Known as | Mirodenafilo | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297518 ↗ |
| Known as | SK-3530 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297518 ↗ |
| Known as | SK3530 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00351065 ↗ |
| Action | Inhibit | “The PDE5 inhibitor, SK3530, is expected to be taken concomitantly with food.” NCT00443625 ↗ |
| Modality | Small molecule | — CHEMBL4297518 ↗ |
| Route | Oral | “after oral administration” NCT00351065 ↗ |